Mosaic ImmunoEngineering Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Selling, General & Admin	0.55	0.7	0.96	1.58	2.05	Upgrade
Research & Development	0.06	0.18	0.44	1.05	1.46	Upgrade
Operating Expenses	0.62	0.88	1.4	2.63	3.5	Upgrade
Operating Income	-0.62	-0.88	-1.4	-2.63	-3.5	Upgrade
Interest Expense	-0.08	-0.08	-0.07	-0.07	-0.03	Upgrade
Interest & Investment Income	0	0	0	0	0	Upgrade
Other Non Operating Income (Expenses)	0.01	0.04	0.05	0.06	-0.02	Upgrade
EBT Excluding Unusual Items	-0.69	-0.92	-1.42	-2.64	-3.55	Upgrade
Gain (Loss) on Sale of Investments	-	-	0.43	0.34	-	Upgrade
Other Unusual Items	-	-0	-0.02	-0.08	-0.13	Upgrade
Pretax Income	-0.69	-0.92	-1.01	-2.38	-3.68	Upgrade
Income Tax Expense	0	0	0	0	0	Upgrade
Net Income	-0.69	-0.92	-1.01	-2.38	-3.68	Upgrade
Net Income to Common	-0.69	-0.92	-1.01	-2.38	-3.68	Upgrade
Shares Outstanding (Basic)	7	7	7	7	7	Upgrade
Shares Outstanding (Diluted)	7	7	7	7	7	Upgrade
Shares Change (YoY)	-	-	0.01%	7.79%	792.16%	Upgrade
EPS (Basic)	-0.10	-0.13	-0.14	-0.33	-0.55	Upgrade
EPS (Diluted)	-0.10	-0.13	-0.14	-0.33	-0.55	Upgrade
EBIT	-0.62	-0.88	-1.4	-2.63	-3.5	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.